Pharmacoeconomic Analysis of Three Therapeutic Schemes for Chronic Hepatitis B / 中国药房

ABSTRACT

OBJECTIVE:To evaluate the economic effects of three therapeutic schemes for chronic hepatitis B.METHODS:116 patients with chronic hepatitis B were divided into 3 groupsGroup A(n=38) received lamivudine(100 mg?d-1,po) for 6 months;Group B(n=38) received IFN?-2b(3million IU?d-1,im) for 4 weeks followed by IFN?-2b(im,3million IU,qod);Group C(n=40) received IFN?-2b(3million IU?d-1,im) for 4 weeks followed by IFN?-2b(im,3million IU,qod) plus lamivudine(po,100 mg?d-1).The course of treatment for the three groups all lasted for 6 months.The cost-effectiveness of the three groups was evaluated using the principle of pharmacoeconomics.RESULTS:In A,B,and C groups,the costs were 3 420,12 168 and 15 588 Yuan,respectively,and the HBV-DNA negative changing rates were 44.7%,47.4% and 67.5%,respectively.The increment in cost for one more unit of effectiveness was 324 000.00 Yuan in Group B and 53 368.42 Yuan in Group C as compared with Group A.CONCLUSION:Scheme C is the optimal one pharmacoeconoically.